TapImmune Inc. — FY 2017 Form 10-K Summary
Entity and period: The filing is for TapImmune Inc. (Nasdaq: TPIV), for the fiscal year ended December 31, 2017, and was filed March 23, 2018. The request identifies Marker Therapeutics, Inc.; that name does not match the registrant in the supplied filing. This is an annual report, not a standalone fourth-quarter report.
Business context
TapImmune was a clinical-stage immuno-oncology company developing peptide vaccines TPIV200 (Folate Receptor Alpha) and TPIV100/110 (HER2/neu+), plus its preclinical PolyStart DNA-expression platform. It reported no product sales or approved products and relied on financing, collaborators and grants to fund development.
Financial performance and liquidity
| Metric | FY 2017 / Dec. 31, 2017 | FY 2016 / Dec. 31, 2016 |
|---|---|---|
| Revenue from product sales | None | None |
| Net loss | $11.0 million; $1.16 per basic and diluted share | $2.5 million; $0.36 basic and $0.72 diluted per share |
| Operating expenses | $11.7 million | $8.5 million |
| Research and development | $5.3 million | $3.8 million |
| General and administrative | $6.4 million | $4.7 million |
| Cash used in operating activities | $8.44 million | $6.51 million |
| Cash | $5.13 million | $7.85 million |
| Working capital / stockholders’ equity | $3.66 million | $6.18 million |
| Total liabilities | $1.52 million | $1.74 million |
Margins are not meaningful because the company had no product revenue. Operating expenses rose about 37%; R&D increased about 38% and G&A about 37%, primarily reflecting clinical-program spending, compensation and stock-based compensation. The filing reports $2.74 million of stock-based compensation in 2017. No material conventional interest-bearing debt is reported; the balance sheet includes a $5,000 promissory note and a $9,000 warrant liability at year-end.
Financing activities provided $5.72 million in 2017, including net proceeds from a June private placement and warrant exercises. Cash declined $2.72 million during the year. Management estimated existing cash would fund operations only into the third quarter of 2018 and said substantial additional capital would be needed. The auditor’s report and management disclosures raise substantial doubt about the company’s ability to continue as a going concern.
Material changes, outlook and risks
- Loss comparison: Net loss widened substantially, partly because 2016 included a $5.94 million noncash gain from changes in warrant fair value, compared with only $5,500 in 2017. The 2017 results also included a $492,000 debt-extinguishment gain and $183,000 of grant income; these items affect year-to-year comparability.
- Clinical programs: TPIV200 Phase II studies included trials in triple-negative breast cancer and ovarian cancer; the company reported completion of enrollment in its 80-patient company-sponsored breast-cancer study and planned interim data in mid-2018. It reported first enrollment in its 120-patient platinum-sensitive ovarian-cancer study and planned an interim analysis after 50% enrollment. A 280-patient Mayo Clinic breast-cancer study was supported by a $13.3 million U.S. Department of Defense grant; the company supplied vaccine and expected reimbursement for manufacturing costs. The filing also described a 40-patient platinum-resistant ovarian-cancer study with Memorial Sloan Kettering and AstraZeneca’s durvalumab.
- Additional development plans: TapImmune planned an amended IND and further clinical development for TPIV110, and continued preclinical work and patent development for PolyStart. These are plans, not assured milestones or outcomes.
- Capital and dilution: Further equity, debt, partnership or other financing was necessary to sustain operations. The June 2017 financing raised $6.2 million gross, with $0.8 million of fees and legal costs; warrants were issued and existing warrant exercise prices were reduced. Future financing could dilute existing holders or impose senior claims or operating restrictions.
- Other risks and contingencies: The company depended on third-party manufacturers, collaborators and clinical sites; clinical, regulatory, intellectual-property and patient-enrollment outcomes were uncertain. It disclosed potential cash payments to certain warrant holders if required registration statements were ineffective or registered shares could not be delivered. No material active litigation was reported. Management said disclosure controls and internal control over financial reporting were effective and that previously identified material weaknesses had been remediated; the auditor did not audit internal controls.
Key facts for investors to verify
- Confirm the registrant identity: the filing names TapImmune Inc., not Marker Therapeutics, Inc.
- Review the audited financial statements and going-concern disclosures, including the runway estimate and subsequent financing activity.
- Check clinical-trial registries and company updates for actual enrollment, interim results, safety findings and changes to trial timelines.
- Assess outstanding warrants, repricing terms, registration-statement status and potential dilution or cash-settlement exposure.
- Verify the amount and conditions of grant funding, including which trial costs are covered and which costs remain TapImmune’s responsibility.